{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:06:29Z","timestamp":1791428789874,"version":"4.3.3"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T00:00:00Z","timestamp":1449532800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007418","name":"Ajinomoto Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007418","name":"Ajinomoto Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1053\/j.gastro.2015.08.044","type":"journal-article","created":{"date-parts":[[2015,8,29]],"date-time":"2015-08-29T18:27:55Z","timestamp":1440872875000},"page":"1775-1783.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Safety and Efficacy of AJM300, an Oral Antagonist of \u03b14 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis"],"prefix":"10.1053","volume":"149","author":[{"given":"Naoki","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Motoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2015.08.044_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2015.08.044_bib2","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/ibd.20453","article-title":"Lymphocyte homing and its role in the pathogenesis of IBD","volume":"14","author":"Eksteen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2015.08.044_bib3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1046\/j.1440-1827.2002.01365.x","article-title":"Differential expression of mucosal addressin cell adhesion molucule-1 (MAdCAM-1) in ulcerative colitis and Crohn\u2019s disease","volume":"52","author":"Arihiro","year":"2002","journal-title":"Pathol Int"},{"key":"10.1053\/j.gastro.2015.08.044_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2567.2005.02225.x","article-title":"Therapeutic anti-integrin (\u03b14 and \u03b1L) monoclonal antibodies: two-edged swords?","volume":"116","author":"Gonz\u00e1lez-Amaro","year":"2005","journal-title":"Immunology"},{"key":"10.1053\/j.gastro.2015.08.044_bib5","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1053\/j.gastro.2015.08.044_bib6","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.08.044_bib7","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn\u2019s disease: results of the ENCORE trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2015.08.044_bib8","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.08.044_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.08.044_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2015.08.044_bib11","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2015.08.044_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2015.08.044_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.drudis.2007.05.001","article-title":"Alpha4-integrin antagonism\u2014an effective approach for the treatment of inflammatory\u00a0diseases?","volume":"12","author":"Davenport","year":"2007","journal-title":"Drug Discovery Today"},{"key":"10.1053\/j.gastro.2015.08.044_bib14","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1177\/0091270004270147","article-title":"Pharmacokinetics, safety, and tolerability of R411, a dual \u03b14\u03b21-\u03b14\u03b27 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers","volume":"44","author":"Hijazi","year":"2004","journal-title":"J\u00a0Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2015.08.044_bib15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1474-4422(11)70299-X","article-title":"Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"11","author":"Miller","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.gastro.2015.08.044_bib16","unstructured":"Makino S, Okuzumi T, Yoshimura T, et\u00a0al. Inventors; AJINOMOTO CO, Inc., assignee. Phenylalanine derivatives. Patent application. WO02\/16329. February 28,\u00a02002."},{"key":"10.1053\/j.gastro.2015.08.044_bib17","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1053\/j.gastro.2011.02.015","article-title":"Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory\u00a0bowel diseases","volume":"140","author":"Villablanca","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2015.08.044_bib18","doi-asserted-by":"crossref","first-page":"A181","DOI":"10.1016\/S0016-5085(09)60816-7","article-title":"Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn\u2019s disease\u2014a randomized, double-blind, placebo-controlled trial","volume":"136","author":"Takazoe","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2015.08.044_bib19","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1016\/j.crohns.2013.03.014","article-title":"Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice","volume":"7","author":"Sugiura","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2015.08.044_bib20","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study","volume":"317","author":"Schreoder","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.08.044_bib21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/gut.32.2.174","article-title":"Microscopic activity in ulcerative colitis: what does it mean?","volume":"32","author":"Riley","year":"1991","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2015.08.044_bib22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ibd.20997","article-title":"Importance of mucosal healing in ulcerative colitis","volume":"16","author":"Lichtenstein","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2015.08.044_bib23","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2015.08.044_bib24","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ibd.21896","article-title":"Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study","volume":"8","author":"Parikh","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1053\/j.gastro.2015.08.044_bib25","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2015.08.044_bib26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s11910-013-0408-6","article-title":"Progressive multifocal leukoencephalopathy in multiple sclerosis","volume":"13","author":"Chalkley","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1053\/j.gastro.2015.08.044_bib27","doi-asserted-by":"crossref","first-page":"S41.002","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.S41.002","article-title":"Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY-2","volume":"78","author":"Bozic","year":"2012","journal-title":"Neurology"},{"key":"10.1053\/j.gastro.2015.08.044_bib28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1053\/j.gastro.2015.08.044_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"International natalizumab multiple sclerosis trial group. A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N\u00a0Engl J Med"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851501241X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650851501241X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:42:38Z","timestamp":1762162958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650851501241X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S001650851501241X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2015.08.044","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of AJM300, an Oral Antagonist of \u03b14 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2015.08.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}